Evertz Technologies Limited (OTCMKTS:EVTZF) Short Interest Up 14.6% in October
Evertz Technologies Limited (OTCMKTS:EVTZF – Get Free Report) saw a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 47,100 shares, an increase of 14.6% from the October 15th total of 41,100 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover […]
Evertz Technologies Limited (OTCMKTS:EVTZF) Short Interest Up 14.6% in October
Evertz Technologies Limited (OTCMKTS:EVTZF – Get Free Report) saw a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 47,100 shares, an increase of 14.6% from the October 15th total of 41,100 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover […]
Leave a Reply
More Stories
Victory Capital Management Inc. Sells 324,271 Shares of Skyline Champion Co. (NYSE:SKY)
Victory Capital Management Inc. decreased its position in shares of Skyline Champion Co. (NYSE:SKY – Free Report) by 48.4% in...
Crown Castle Inc. (NYSE:CCI) Stock Holdings Lessened by Victory Capital Management Inc.
Victory Capital Management Inc. lessened its holdings in shares of Crown Castle Inc. (NYSE:CCI – Free Report) by 2.6% in...
JELD-WEN Holding, Inc. (NYSE:JELD) Shares Acquired by Victory Capital Management Inc.
Victory Capital Management Inc. boosted its position in JELD-WEN Holding, Inc. (NYSE:JELD – Free Report) by 1,167.9% in the third...
Victory Capital Management Inc. Buys 12,854 Shares of Simon Property Group, Inc. (NYSE:SPG)
Victory Capital Management Inc. lifted its stake in shares of Simon Property Group, Inc. (NYSE:SPG – Free Report) by 6.0%...
G Mining Ventures Corp. (OTCMKTS:GMINF) Sees Significant Growth in Short Interest
G Mining Ventures Corp. (OTCMKTS:GMINF – Get Free Report) was the recipient of a significant increase in short interest during...
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, Robert W. Baird Analyst Says
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) had its price objective hoisted by analysts at Robert W. Baird from $32.00...